[
    [
        {
            "time": "",
            "original_text": "华东医药利拉鲁肽减肥适应症已完成III期临床入组领跑国内糖尿病及减肥领域",
            "features": {
                "keywords": [
                    "利拉鲁肽",
                    "减肥",
                    "糖尿病",
                    "III期临床",
                    "华东医药"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物技术"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "华东医药利拉鲁肽减肥适应症已完成III期临床入组领跑国内糖尿病及减肥领域",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021",
            "original_text": "华东医药：公司利拉鲁肽注射液减肥适应症目前已经完成III期临床入组，正在进随访，计划于2021年底前开展上市申报工作",
            "features": {
                "keywords": [
                    "利拉鲁肽",
                    "注射液",
                    "减肥",
                    "III期临床",
                    "上市申报",
                    "华东医药"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物技术"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "华东医药：公司利拉鲁肽注射液减肥适应症目前已经完成III期临床入组，正在进随访，计划于2021年底前开展上市申报工作",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "华东医药：目前公司已完成国内pre-IND资料递交",
            "features": {
                "keywords": [
                    "华东医药",
                    "pre-IND",
                    "资料递交"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "研发"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "华东医药：目前公司已完成国内pre-IND资料递交",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-08-29",
            "original_text": "华东医药：公司全球独家胶原蛋白刺激剂长效微球Ellansé伊妍仕已于8月29日正式登陆中国大陆市场",
            "features": {
                "keywords": [
                    "华东医药",
                    "Ellansé",
                    "伊妍仕",
                    "胶原蛋白",
                    "长效微球",
                    "中国大陆市场"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "美容医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "华东医药：公司全球独家胶原蛋白刺激剂长效微球Ellansé伊妍仕已于8月29日正式登陆中国大陆市场",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "华东医药：公司利拉鲁肽注射液“适用于成人2型糖尿病患者控制血糖”的上市许可申请已获得国家药品监督管理局（NMPA）受理",
            "features": {
                "keywords": [
                    "利拉鲁肽",
                    "注射液",
                    "2型糖尿病",
                    "血糖控制",
                    "NMPA",
                    "华东医药"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "糖尿病治疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "华东医药：公司利拉鲁肽注射液“适用于成人2型糖尿病患者控制血糖”的上市许可申请已获得国家药品监督管理局（NMPA）受理",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业：风物长宜放眼量",
            "features": {
                "keywords": [
                    "医药生物",
                    "行业展望"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物技术"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业：风物长宜放眼量",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 5,
                "Entity_Density": 1,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        }
    ]
]